ArticleOncogene1999
RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 59 citations in OpenAlex.
- 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) induces apoptosis in breast cancer cells through inhibiting of Mcl-1 expression.Scientific reports · 2023Article
- Article
- Exosomal Metastasis‑Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer.International journal of biological sciences · 2018Article
- Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.Journal of medicinal chemistry · 2016Article
- Apoptosis signal-regulating kinase 1 promotes Ochratoxin A-induced renal cytotoxicity.Scientific reports · 2015Article
- The basal transcription machinery as a target for cancer therapy.Cancer cell international · 2014Article
- Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.British journal of pharmacology · 2014Article
- Implication of transcriptional repression in compound C-induced apoptosis in cancer cells.Cell death & disease · 2013Article
- Low expression of cyclinH and cyclin-dependent kinase 7 can decrease the proliferation of human esophageal squamous cell carcinoma.Digestive diseases and sciences · 2013Article
- Involvement of cyclin K posttranscriptional regulation in the formation of Artemia diapause cysts.PloS one · 2012Article
- Article
- Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.Investigational new drugs · 2011Article
- Awakening guardian angels: drugging the p53 pathway.Nature reviews. Cancer · 2009Review
- Article
- Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis.BMC cancer · 2008Article
- The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome.The EMBO journal · 2003Article
- Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation.Oncogene · 2001Article
- Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways.Oncogene · 2000Article
- Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus.Oncogene · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most modern chemo- and radiotherapy treatments of human cancers use the DNA damage pathway, which induces a p53 response leading to either G1 arrest or apoptosis. However, such treatments can induce mutations and translocations leading to secondary malignancies or recurrent disease, which often have a poor prognosis because of resistance to therapy. Here we report that 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), an inhibitor of CDK7 TFIIH-associated kinase, CKI and CKII kinases, blocking RNA polymerase II in the early elongation stage, triggers p53-dependent apoptosis in human colon adenocarcinoma cells in a transcription independent manner. The fact that DRB kills tumour-derived cells without employment of DNA damage gives rise to the possibility of the development of a new alternative chemotherapeutic treatment of tumours expressing wild type p53, with a decreased risk of therapy-related, secondary malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.